Skip to content

Study on the mechanisms of the regulatory role of Porphyromonas gingivalis on Th17 in promoting oral mucosal injury in AIDS patients

Study on the mechanisms of the regulatory role of Porphyromonas gingivalis on Th17 in promoting oral mucosal injury in AIDS patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108861
Enrollment
Unknown
Registered
2025-09-08
Start date
2025-01-16
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immune Deficiency Syndrome

Interventions

HIV Non-Oral Lesion Group:N/A
AIDS Oral Lesion Group:N/A
Healthy Control Group:N/A

Sponsors

Beijing Youan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.HIV Non-Oral Lesion Group:(1) Age 18 years or older;(2) No lesions or damage to the oral mucosa;(3) Patients who are HIV antibody positive. 2.AIDS Oral Lesion Group:(1) Meet the diagnostic criteria for AIDS;(2) Age 18 years or older;(3) Presence of oral lesions: patients with non-Hodgkin lymphoma. 3.Healthy Control Group:(1) Age 18 years or older;(2) No lesions or damage to the oral mucosa;(3) Patients who are HIV antibody negative.

Exclusion criteria

Exclusion criteria: 1.HIV Non-Oral Lesion Group:(1) Pregnant or breastfeeding women;(2) Individuals with lesions or damage to the oral mucosa;(3) Use of oral or topical antibiotics, glucocorticoids, or immunomodulatory drugs within 3 months prior to examination;(4) Individuals who did not sign the informed consent form. 2.AIDS Oral Lesion Group:(1) Individuals with non-HIV-related oral infections or oral tumor diseases;(2) Patients with psychiatric disorders;(3) Individuals with a history of drug abuse;(4) Pregnant or breastfeeding women;(5) Individuals who did not sign the informed consent form. 3.Healthy Control Group:(1) Pregnant or breastfeeding women;(2) Individuals with lesions or damage to the oral mucosa;(3) Use of oral or topical antibiotics, glucocorticoids, or immunomodulatory drugs within 3 months prior to examination;(4) Individuals who did not sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Th17 cell count in whole blood;IL-17 concentration in saliva supernatant;

Countries

China

Contacts

Public ContactYing Guo

Beijing Youan Hospital, Capital Medical University

153505774@qq.com+86 185 1568 7688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026